The influenza replication blocking inhibitor LASAG does not sensitize human epithelial cells for bacterial infections

Abstract

Severe influenza virus (IV) infections still represent a major challenge to public health. To combat IV infections, vaccines and antiviral compounds are available. However, vaccine efficacies vary with very limited to no protection against newly emerging zoonotic IV introductions. In addition, the development of resistant virus variants against currently available antivirals can be rapidly detected, in consequence demanding the design of novel antiviral strategies. Virus supportive cellular signaling cascades, such as the NF-κB pathway, have been identified to be promising antiviral targets against IV in in vitro and in vivo studies and clinical trials. While administration of NF-κB pathway inhibiting agents, such as LASAG results in decreased IV replication, it remained unclear whether blocking of NF-κB might sensitize cells to secondary bacterial infections, which often come along with viral infections. Thus, we examined IV and Staphylococcus aureus growth during LASAG treatment. Interestingly, our data reveal that the presence of LASAG during superinfection still leads to reduced IV titers. Furthermore, the inhibition of the NF-κB pathway resulted in decreased intracellular Staphylococcus aureus loads within epithelial cells, indicating a dependency on the pathway for bacterial uptake. Unfortunately, so far it is not entirely clear if this phenomenon might be a drawback in bacterial clearance during infection.

Dual Host and Pathogen RNA-Seq Analysis Unravels Chicken Genes Potentially Involved in Resistance to Highly Pathogenic Avian Influenza Virus Infection

“…Three of the downregulated genes (PLAU, VCAM1, TNFRSF1A) belong to the NF-kB signaling pathway, suggesting that the activation of this inflammatory pathway might benefit virus replication. In fact, some drugs inhibit this pathway as a strategy against influenza viruses (65)(66)(67). However, this host signaling pathway seems to play a controversial role in AIV infection.…”

D,L-Lysine-Acetylsalicylate + Glycine (LASAG) Reduces SARS-CoV-2 Replication and Shows an Additive Effect with Remdesivir

“…A newer formulation of ASA, D,L-lysine-acetylsalicylate + glycine (LASAG), is a water-soluble salt of ASA. The two amino acids lysine and glycine improve the stability and tolerability of the active compound ASA (Supplementary Figure S1) [31,[33][34][35]. LASAG is approved as Aspirin ® i.v.…”